Frontier Bio Wins Phase 1 of $7M NIH Challenge for AI-Powered Blood-Brain Barrier Testing

Frontier Bio, a biotechnology company engineering advanced human tissues, has been named a Phase 1 winner of the Complement-ARIE New Approach Methodologies (NAMs) Reduction to Practice Challenge, a national competition run by the NIH Common Fund in collaboration with the FDA and EPA, and administered through the NASA Tournament Lab. The Phase 1 win comes with a cash award and advances Frontier Bio, one of up to 20 winning teams, into the subsequent phases of the multi-year competition, which carries a total prize pool of $7 million.

​

The challenge advances NAMs, human-based laboratory and computational methods that reduce reliance on animal testing while improving the accuracy of early drug development.

​

The win lands as U.S. regulators move toward the human-based testing that Frontier Bio builds. The FDA's 2025 roadmap, enabled by the FDA Modernization Act 2.0, lays out a plan to phase out animal-testing requirements in favor of human-based and computational methods. Bringing a single drug to market costs an estimated $2.6 billion and takes more than a decade, and fewer than one in ten central nervous system drug candidates that reach clinical trials make it to patients, in large part because the blood-brain barrier blocks about 98% of small-molecule drugs and nearly all biologics.

​

Frontier Bio's winning platform, NeuroTraX-AI, pairs a scalable, human-cell-based microphysiological system that recreates the neurovascular unit with an artificial intelligence layer that quantifies blood-brain-barrier disruption from standard, label-free microscope images. It measures how drugs, cell therapies, and injury affect the human barrier, whether an agent crosses it, disrupts it, or leaves it intact. The result is quantitative, spatially resolved data for faster, lower-cost testing.